Who
Erin Burkhart
SVP, Controllership
Company insider
Files Form 4 as: SVP, Controllership, Gilead Sciences; GVP, Chief Accounting Officer, BioMarin Pharmaceutical.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $560K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 16 May 2022
- Last trade
- 22 Sep 2026
- Last filed
- 23 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Sep 2026filed 23 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —2,223 | filing |
| 22 Sep 2026filed 23 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $117K768 at $152.67 | filing |
| 22 Sep 2026filed 23 Sep 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,223 | filing |
| 22 Sep 2026filed 23 Sep 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,223 | filing |
| 22 Sep 2026filed 23 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —2,223 | filing |
| 22 Sep 2026filed 23 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $117K768 at $152.67 | filing |
| 10 Mar 2026filed 12 Mar 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,355 | filing |
| 10 Mar 2026filed 12 Mar 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,455 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,355 | filing |
| 10 Mar 2026filed 12 Mar 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,455 at $0.00 | filing |
| 22 Sep 2025filed 23 Sep 2025 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,890 | filing |
| 20 May 2025filed 20 May 2025 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $106K1,786 at $59.31 | filing |
| 19 May 2025filed 20 May 2025 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $59K996 at $59.27 | filing |
| 19 Mar 2025filed 20 Mar 2025 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $93K1,295 at $71.52 | filing |
| 17 Mar 2025filed 18 Mar 2025 | BMRN BioMarin Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —9,230 at $0.00 | filing |
| 17 Mar 2025filed 18 Mar 2025 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —5,970 at $0.00 | filing |
| 14 Mar 2025filed 18 Mar 2025 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $57K823 at $69.44 | filing |
| 24 Feb 2025filed 25 Feb 2025 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $92K1,344 at $68.38 | filing |
| 13 Aug 2024filed 15 Aug 2024 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $64K714 at $90.00 | filing |
| 17 May 2024filed 20 May 2024 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $76K993 at $76.97 | filing |
News
Critical Survey: XTL Biopharmaceuticals (NASDAQ:XTLB) & BioMarin Pharmaceutical (NASDAQ:BMRN)BMRN · tickerreport.com · 18 Oct 2026BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Upgraded by UBS GroupBMRN · tickerreport.com · 17 Oct 2026BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Expected to Rise, Barclays Analyst SaysBMRN · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Erin Burkhart; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.